Movfor - Molnupiravir 200mg Capsules, Official Website of MOVFOR

1. MOVFORMolnupiravir(http://www.movfor.co.in/)

2. Hetero Announces Approval and Launch of Movfor • Hetero is a globally renowned vertically integrated pharmaceutical organization announced on 28 December, 2021. The Drug Controller General of India (DCGI) has granted it permission for manufacture and marketing of Molnupiravir capsules 200 mg (Movfor). • Hetero’s Movfor will be made available in a 40 capsule pack (200 mg per capsule) and will be marketed by its associate company ‘Hetero Healthcare’ in India with the support of its strong distribution network across the country. This approval consolidates India’s efforts to address the world’s greatest health threats, i.e., COVID-19. • Hetero strives to Improve access to critical medicines will always remain the top priority and maintain highest quality standards.

3. About Molnupiravir • MOVFOR belongs to COVID 19 Management therapy of COVID 19 Management and it is available in 1 form : Movfor 200Mg Capsules to cease the pandemic prevailing all over • It is an investigational, orally bioavailable medicine indicated for restricted emergency use in India to treat adult patients affected with COVID 19, with SpO2>93%, or who have a high risk of disease progression or hospitalization. • Movfor 200 MG Capsules has its active agent as Molnupiravir which is a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses, including SARS-CoV2, that causes COVID 19. It is active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS (Middle East respiratory syndrome, a viral respiratory disease caused by a novel coronavirus).

4. MovforIs Restricted for • Patients less than 18 years of age. • Patients requiring immediate hospitalization due to COVID-19 at that stage, (however, if it was initiated before hospitalization due to COVID-19, it may be continued). • Longer than 5 consecutive days. • Pre-exposure or post-exposure prophylaxis for prevention of COVID-19. • Pregnant women.

5. How to Intake the Medicine For oral use: • Molnupiravir 200 mg capsules can be taken with or without food. • The capsules should be swallowed whole with a sufficient amount of fluid (e.g., a glass of water). The capsules should not be opened, crushed or chewed. Adults: • The recommended dose of Molnupiravir is 800 mg (four 200 mg capsules) taken orally every 12 hours for 5 days. • The safety and efficacy of molnupiravir when administered for periods longer than 5 days have not been established. • Molnupiravir should be administered as soon as possible after a diagnosis of COVID-19 has been made and within 5 days of symptom onset.

6. Use of Medicine in Health-risk People Elderly: No dose adjustment of Molnupiravir is required based on age. Renal impairment: No dose adjustment is required for patients with renal impairment. Hepatic impairment: No dose adjustment is required for patients with hepatic impairment. Paediatric population: The safety and efficacy of Molnupiravir in patients below 18 years of age have not been established. No data is available. Pregnancy: There is no data from the use of molnupiravir in pregnant women. Studies in animals have shown reproductive toxicity. Molnupiravir is not recommended during pregnancy. Females of childbearing potential should use reliable method of contraception correctly and consistently, as applicable, for the duration of treatment and for 4 days after the last dose of molnupiravir.

7. Males of reproductive potential who are sexually active with females of childbearing potential should use a reliable method of contraception correctly and consistently during treatment and for at least 3 months after the last dose. • Breast-feeding: It is unknown whether molnupiravir or any of the components of molnupiravir are present in human milk, affect human milk production, or have effect on the breastfed infant. Animal lactation studies with molnupiravir have not been conducted. • Based on the potential for adverse reactions on the infant from molnupiravir, breast-feeding is not recommended during treatment and for 4 days after the last dose of molnupiravir. • Fertility: There were no effects on female or male fertility in rats at NHC exposures approximately 2 and 6 times respectively, the exposure in humans at the recommended human dose (RHD).

8. What if you Skip the Dosage? Missed dose: • If the patient misses a dose of Molnupiravir within 10 hours of the time it is usually taken, the patient should take the skipped dose as soon as possible and resume the normal dosing schedule. • If a patient misses a dose by more than 10 hours, the patient should not take the missed dose and instead take the next dose at the regularly scheduled time. The patient should not double the dose to make up for a missed dose.

9. Contraindications:Hypersensitivity to the active substance or to any of its components Precautions for Use: Limited clinical data available for molnupiravir. • Take the medicine with or without food. • It is not recommended to pregnant/planning for pregnancy, and breastfeeding women. • Take the dose as prescribed by your doctor. Do not take the wrong dose or it probably result in complications. • Do not skip/overdose/overlap the dose of the medicine. • Both male and female are advised to use contraception pills while using the medicine. • Tell your doctor if you are allergic to any of the active or inactive ingredient of the medicine. • Molnupiravir is not recommended in patients less than 18 years of age as it may affect bone and cartilage growth. The safety and efficacy of molnupiravir have not been established in pediatric patients.

10. Side Effects No side effects have been detected in trial volunteers until now! The medicine might cause affect the foetal development and cause birth defects in unborn baby. Interactions No drug interactions have been identified based on the limited available data. No clinical interaction studies have been performed with molnupiravir. Molnupiravir is hydrolysed to n-hydroxycytidine (NHC) prior to reaching systemic circulation. Uptake of NHC and metabolism to NHC-TP are mediated by the same pathways involved in endogenous pyrimidine metabolism. NHC is not a substrate of major drug metabolising enzymes or transporters. Based on in vitro studies, neither molnupiravir nor NHC are inhibitors or inducers of major drug metabolising enzymes or inhibitors of major drug transporters. Therefore, the potential for molnupiravir or NHC to interact with concomitant medications is considered unlikely.

11. Availability • Movfor 200 MG Capsules is available with Hetero Healthcare now in a 40 capsule pack (200 MG per capsule). We are the manufacturers, bulk suppliers and distributors of the medicine across India to combat Corona. • Visit : https://www.heterohealthcare.com/molnupiravir-movfor-200mg-capsules • Visit : http://www.movfor.co.in/

12. Corporate Address Hetero Healthcare Limited S.no: 80-84, Melange Towers, Patrika Nagar, Madhapur, Hyderabad, Telangana 500081 Phone: 1800 103 4696 Email: lead@heterohealthcare.com Follow Us:

13. THANK YOU